Knight Therapeutics Inc. (GUD : TSX)
Common Stock
$10.73
CAD
+0.02 (0.19%)
Last updated: 2026-10-08
Follow GUD
GUD
Knight Therapeutics Inc.
WealthAwesomePerformance
1 Day
+0.19%
1 Week
+0.85%
1 Month
+8.38%
YTD
+81.56%
Key Statistics
Market Cap
$1.05B
52W High
$10.82
52W Low
$5.66
P/E Ratio
71.53
50 Day MA
$9.90
200 Day MA
$8.13
Beta
-0.01
Dividend Yield
-
Advertisement
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 10/8/2026 | $10.73 | $10.82 | $10.63 | $10.73 | $10.73 | 48,650 |
| 10/7/2026 | $10.31 | $10.79 | $10.31 | $10.71 | $10.71 | 61,289 |
| 10/6/2026 | $10.41 | $10.57 | $10.37 | $10.54 | $10.54 | 68,051 |
| 10/5/2026 | $10.34 | $10.36 | $10.21 | $10.36 | $10.36 | 62,605 |
| 10/2/2026 | $10.67 | $10.80 | $10.31 | $10.32 | $10.32 | 63,555 |
| 10/1/2026 | $10.60 | $10.64 | $10.47 | $10.64 | $10.64 | 56,169 |
| 9/30/2026 | $10.35 | $10.74 | $10.28 | $10.59 | $10.59 | 118,469 |
| 9/29/2026 | $10.20 | $10.41 | $10.16 | $10.35 | $10.35 | 53,648 |
| 9/28/2026 | $10.24 | $10.30 | $10.18 | $10.27 | $10.27 | 34,485 |
| 9/25/2026 | $10.24 | $10.29 | $10.10 | $10.29 | $10.29 | 60,736 |
Analyst Price Targets
Based on analyst covering GUD · as of Sep 17, 2026
Wall Street analysts forecast GUD stock price to rise 4.2% over the next 12 months.
Consensus
NeutralBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$11.19
+4.2% Upside
Current Price
C$10.73
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on GUD's historical volatility
30-Day Vol
23.6%
Annualized
90-Day Vol
26.9%
Annualized
Trend (90d)
+38.1%
Annualized drift
90d Mean
C$12.29
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$11.23 | C$10.35 – C$12.18 |
| 60 trading days | C$11.75 | C$10.47 – C$13.18 |
| 90 trading days | C$12.29 | C$10.68 – C$14.16 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Knight Therapeutics Inc.
Knight Therapeutics Inc. focuses on acquiring, in-licensing, out-licensing, marketing, and commercializing prescription pharmaceutical products in Canada and Latin America. The company offers Minjuvi for relapsed or refractory diffuse large B-cell lymphoma; Pemazyre for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Tavalisse for the treatment of chronic immune thrombocytopenia; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; Lenvima for advanced renal cell cancer; Zyvalix for metastatic prostate cancer; Karfib for relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; Bapoci for brest cancer; Xetrane for multiple myeloma; Rembre for chronic myeloid leukemia; Imvexxy for moderate to severe dyspareunia; Bijuva for moderate to severe vasomotor symptoms; IPX203 for Parkinson's disease; Qelbree for attention-deficit hyperactivity disorder; Jornay PM for attention-deficit hyperactivity disorder; and Crexon for Parkinson's disease. In addition, it offers Salofalk for ulcerative colitis; Ursofalk for biliary cirrhosis; Fibridoner for idiopathic pulmonary fibrosis; Ibsrela for IBS-C; and Exelon for symptomatic treatment of mild to moderately severe dementia in people with Alzheimer's and Parkinson's disease. Further, it offers Niktimvo; Zynyz; Gemtesa; Orgovyx; Myfembree; Onicit; Jornay PM and Crexont capsules; and Palbocil and Bapocil for treatment of patients with hormone receptor positive. Additionally, it provides finances to other life science companies; and invests in life sciences venture capital funds. The company was incorporated in 2013 and is based in Montreal, Canada.
Financials
- Revenue (TTM)
- $547.31M
- EBITDA
- $81.16M
- Profit Margin
- 2.72%
- ROE (TTM)
- 1.91%
- EPS (Diluted)
- 0.15
- Book Value
- 8.13
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE ReportExplore More
Advertisement
Common Questions About GUD
Market movers
Recent TSX movers
Top 1-day gainers — updated from our Canadian movers feed.
| Ticker | Name | Price | 1D |
|---|---|---|---|
| FTG | Firan Technology Group Corporation | $32.00 | +25.93% |
| BNG | Bengal Energy Ltd | $0.03 | +25.00% |
| PRN | Profound Medical Corp | $9.84 | +20.59% |
| RCH | Richelieu Hardware Ltd. | $38.63 | +11.39% |
| LUC | Lucara Diamond Corp | $0.15 | +11.11% |
| TVA-B | TVA Group Inc | $2.49 | +10.67% |
| THNC | Thinkific Labs Inc | $2.05 | +10.22% |
| MCB | Mccoy Global Inc | $2.65 | +9.50% |
GUD.TO news timeline
15 articles covering GUD.TO, most recent first
LatestWhat's Going On With Knight Therapeutics Inc. Stock Wednesday?
September 2026
August 2026
- What's Going On With Knight Therapeutics Inc. Stock Thursday?
- What's Going On With Knight Therapeutics Inc. Stock Thursday?
- Why Knight Therapeutics Inc. stock is tanking today
- What's Going On With Knight Therapeutics Inc. Stock Thursday?
- Why Knight Therapeutics Inc. stock fell yesterday
- Why Knight Therapeutics Inc. stock fell yesterday
- Knight Therapeutics Inc. GUD Earnings Miss Estimates by 188.0%
- What's Going On With Knight Therapeutics Inc. Stock Thursday?
- Why Knight Therapeutics Inc. stock is rising today